Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $234.1 million.

  • Heron Therapeutics' Total Liabilities fell 1024.5% to $234.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.1 million, marking a year-over-year decrease of 1024.5%. This contributed to the annual value of $266.8 million for FY2024, which is 402.33% up from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Total Liabilities is $234.1 million, which was down 1024.5% from $259.3 million recorded in Q2 2025.
  • Heron Therapeutics' Total Liabilities' 5-year high stood at $266.8 million during Q4 2024, with a 5-year trough of $114.7 million in Q1 2021.
  • Its 5-year average for Total Liabilities is $242.2 million, with a median of $249.8 million in 2022.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 12467.45% in 2021, then plummeted by 1024.5% in 2025.
  • Heron Therapeutics' Total Liabilities (Quarter) stood at $228.1 million in 2021, then rose by 4.05% to $237.4 million in 2022, then rose by 8.05% to $256.5 million in 2023, then grew by 4.02% to $266.8 million in 2024, then dropped by 12.27% to $234.1 million in 2025.
  • Its Total Liabilities was $234.1 million in Q3 2025, compared to $259.3 million in Q2 2025 and $264.2 million in Q1 2025.